Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2967346 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM4EHSD17B10GAAGLA | |
| SCHEMBL1544895 | 0.80 | ALDH1A1 (0.67) | ALDH1A1KDM4EHSD17B10GAAHPGD | |
| SCHEMBL974759 | 0.74 | ALDH1A1 (0.69) | ALDH1A1KDM4EHSD17B10GAAGLA | |
| SCHEMBL9223454 | 0.73 | ALDH1A1 (0.62) | ALDH1A1KDM4EHSD17B10GAAGLA | |
| SCHEMBL8262279 | 0.73 | ALDH1A1 (0.58) | ALDH1A1KDM4EHSD17B10GAAGLA | |
| SCHEMBL2966770 | 0.72 | ALDH1A1 (0.53) | ALDH1A1KDM4EHSD17B10GAAGLA | |
| SCHEMBL2002380 | 0.72 | DYRK1A (0.41) | LMNAMAPTCYP3A4DYRK1A | |
| SCHEMBL4172596 | 0.71 | ALDH1A1 (0.70) | ALDH1A1KDM4EHSD17B10GAAGLA | |
| SCHEMBL1544564 | 0.71 | ALDH1A1 (0.70) | ALDH1A1KDM4EHSD17B10GAAGLA | |
| SCHEMBL10916439 | 0.71 | ALDH1A1 (1.00) | ALDH1A1KDM4EHSD17B10GAAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101896480-A | Tetrazole derivatives as modulators of metabotropic glutamate receptors (MGLURS) | ASTRAZENECA AB | 2010-11-24 | — | — | CN | claimed |
| EP-2231647-A1 | TETRAZOLE DERIVATES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | claimed |
| US-20090131454-A1 | New compounds 067 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | claimed |
| WO-2009051556-A1 | TETRAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | claimed |
| US-7960422-B2 | Pharmaceutically active compounds containing tetrazolyl and triazolyl rings | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-7960422-B2 | Pharmaceutically active compounds containing tetrazolyl and triazolyl rings | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-7960422-B2 | Pharmaceutically active compounds containing tetrazolyl and triazolyl rings | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-20090131454-A1 | New compounds 067 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131454-A1 | New compounds 067 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131454-A1 | New compounds 067 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| WO-2009051556-A1 | TETRAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131454-A1 | New compounds 067 | UGT2B7, UGT1A7, CYP3A7 | ALDH1A1 1808/4885KDM4E 3734/4885HSD17B10 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.